Yuping Zou MS , Siyu Wei PhD , Qinduo Ren MS, Tianyu Zhou MS, Songlin Lu MS, Ruilin Li MS, Yingnan Ma PhD, Linna Yuan MS, Jiacheng Wang MS, Wei She MS, Xuying Guo PhD, Junxian Tao PhD, Shuo Bi MS, Hongsheng Tian MS, Chen Sun PhD, Haiyan Chen PhD, Jing Xu PhD, Yu Dong MS, Jingxuan Kang PhD, Hongchao Lv PhD, Mingming Zhang PhD
{"title":"Global Burden of Rheumatic Heart Disease (1990-2021), Attributable Risk Factors, and Future Projections","authors":"Yuping Zou MS , Siyu Wei PhD , Qinduo Ren MS, Tianyu Zhou MS, Songlin Lu MS, Ruilin Li MS, Yingnan Ma PhD, Linna Yuan MS, Jiacheng Wang MS, Wei She MS, Xuying Guo PhD, Junxian Tao PhD, Shuo Bi MS, Hongsheng Tian MS, Chen Sun PhD, Haiyan Chen PhD, Jing Xu PhD, Yu Dong MS, Jingxuan Kang PhD, Hongchao Lv PhD, Mingming Zhang PhD","doi":"10.1016/j.jacbts.2026.101511","DOIUrl":null,"url":null,"abstract":"<div><div>Rheumatic heart disease (RHD) is a chronic valvular disorder caused by acute rheumatic fever. It mostly affects the mitral valve and leads to thickening. The present study employs the GBD (Global Burden of Diseases, Injuries, and Risk Factors Study 2021) to analyze the global burden of RHD. The study investigates trends in incidence, prevalence, disability-adjusted life-years, and mortality from 1990 to 2021 across regions and 204 countries and territories, exploring difference with sex, age, and sociodemographic index. Two-sample Mendelian randomization identified high systolic blood pressure and high body mass index as causal risk factors for RHD. Although there was a slight increase in age-standardized prevalence and incidence rates, there was a decline in mortality and disability-adjusted life-year rates. Projections indicate a persistent upward trend in the incidence of the condition from 2022 to 2050. The findings emphasize the persistent global burden of RHD and underscore the necessity for targeted interventions.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"11 4","pages":"Article 101511"},"PeriodicalIF":8.4000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452302X2600029X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Rheumatic heart disease (RHD) is a chronic valvular disorder caused by acute rheumatic fever. It mostly affects the mitral valve and leads to thickening. The present study employs the GBD (Global Burden of Diseases, Injuries, and Risk Factors Study 2021) to analyze the global burden of RHD. The study investigates trends in incidence, prevalence, disability-adjusted life-years, and mortality from 1990 to 2021 across regions and 204 countries and territories, exploring difference with sex, age, and sociodemographic index. Two-sample Mendelian randomization identified high systolic blood pressure and high body mass index as causal risk factors for RHD. Although there was a slight increase in age-standardized prevalence and incidence rates, there was a decline in mortality and disability-adjusted life-year rates. Projections indicate a persistent upward trend in the incidence of the condition from 2022 to 2050. The findings emphasize the persistent global burden of RHD and underscore the necessity for targeted interventions.
期刊介绍:
JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.